


Contents lists available at ScienceDirect

Asian Pacific Journal of Tropical Biomedicine

journal homepage: www.elsevier.com/locate/apjtb

Document heading doi:10.1016/S2221-1691(15)30350-6

©2015 by the Asian Pacific Journal of Tropical Biomedicine. All rights reserved.

***In vivo* anti-salmonella activity of aqueous extract of *Euphorbia prostrata* Aiton (Euphorbiaceae) and its toxicological evaluation**Donald Sédric Tala¹, Donatien Gatsing^{1*}, Siméon Pierre Chegaing Fodouop^{1,2}, Charles Fokunang³, Fabrice Kengni¹, Merline Namekong Djimeli¹¹Department of Biochemistry, Faculty of Science, University of Dschang, P.O. Box 67 Dschang, Cameroon²Department of Biomedical Sciences, University of Ngaoundéré, P.O. Box 454 Ngaoundéré, Cameroon³Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Cameroon

PEER REVIEW

Peer reviewerDr. Guelmbaye Ndoutamia Anaclét,
University of Doba, Chad.

Tel: 235 66 32 46 67

E-mails: ndoutamiaanaclét@yahoo.fr;
ndoutamia@gmail.com**Comments**

In the present study, it was observed that the aqueous extract of *E. prostrata* Aiton can be used in the treatment of typhoid fever with satisfactory efficacy and safety. However, hematological, biochemical and histopathological analyses indicated that, at relatively higher doses, the liver and kidney could be damaged. Information generated in this study could be the reference for the routine use of aqueous extract of the aforementioned plant in the treatment of typhoid fever after extrapolation in human being.

Details on Page 317

ABSTRACT

Objective: To investigate the *in vivo* anti-salmonella activity and the safety of aqueous extract of *Euphorbia prostrata* (*E. prostrata*), a plant commonly used in Cameroon by traditional healers.

Methods: A *Salmonella typhimurium*-infected rat model was used for the study. The physiological, biochemical and histopathological markers of possible side effects of this extract were studied using standard methods.

Results: The extract had a significant effect on the number of viable *Salmonella typhimurium* recovered from faeces, and could stop salmonellosis after 8 and 10 days of treatment for male and female rats, respectively, with non-toxic doses. However, the biochemical and histopathological analyses revealed that at relatively high doses (≥ 73.48 mg/kg for female and ≥ 122.71 mg/kg for male) the extract could induce liver damage, as illustrated by a rise of serum transaminases' levels and significant inflammation of the parenchyma and portal vein. Side effects were also observed on the kidneys, as shown by both serum and urinary creatinine, and urinary proteins.

Conclusions: The overall results indicate that the aqueous extract of *E. prostrata* has the potential to provide an effective treatment for salmonellosis, including typhoid fever. However, it is necessary to extrapolate these results in large animals, in further studies.

KEYWORDS

Euphorbia prostrata Ait., Typhoid fever, *Salmonella*, Safety**1. Introduction**

Salmonella enterica, which is a group of Gram-negative bacterial pathogens capable of infecting humans and animals, cause significant morbidity and mortality worldwide[1]. Certain serotypes adapted to human, such as *Salmonella typhi* (*S. typhi*) and *Salmonella paratyphi* (*S. paratyphi*), usually cause severe diseases in humans, such as enteric fevers (typhoid and paratyphoid fevers). In most endemic areas like Africa, Asia, and Latin America[2], approximately 90% of enteric fever is typhoid. This disease is an important global health problem with an

estimated 16 million cases and 600000 deaths each year[3]. Typhoid is transmitted by the faecal-oral route via contaminated food and water and is therefore common where sanitary conditions are inadequate and access to clean water is limited. The use of antibiotics is a major strategy for the fight against these bacteria, and antimicrobial agents are commonly used therapeutically and prophylactically in human and animal salmonellosis. However, conventional antityphoid drugs are becoming more and more unavailable to the common man in Africa due to increased cost[4]. Moreover, the typhoid causative organism, *S. typhi*, has rapidly gained resistance to the previously efficacious drugs

*Corresponding author: Prof. Donatien Gatsing, Department of Biochemistry, Faculty of Science, University of Dschang, P.O. Box 67 Dschang, Cameroon.
Tel: +237 677 51 6740
E-mail: gatsingd@yahoo.com

Article history:
Received 11 Sep 2014
Received in revised form 12 Sep 2014
Accepted 20 Nov 2014
Available online 11 Mar 2015

like ciprofloxacin[5]. Hence, there is a need for new antityphoid agents.

Studies have shown that the pathogenicity and virulence of *Salmonella* is host specific[6]. *S. typhi* induces a systemic infection in humans but not in mice or rats, while *Salmonella typhimurium* (*S. typhimurium*) induces a systemic infection in mice and rats (similar to that induced by *S. typhi* in humans) and just a localized gastroenteritis in humans. Thus, salmonellosis induced by *S. typhimurium* in rats has many similarities to the typhoid fever in human, with the primary site of colonization being ileum in both species[7]. So *S. typhimurium*-infected rats or mice have been extensively used as models for the understanding of the pathophysiology of typhoid fever[6,8].

Recently, there has been considerable interest in the use of plant materials as an alternative method of controlling pathogenic microorganisms[9], and many compounds from plants have been shown to be effective against resistant pathogenic bacteria[10]. According to WHO[11], medicinal plants are the best sources to obtain a variety of new herbal drugs. About 80% of individuals from developing countries use traditional medicine, which has substances derived from medicinal plants[11]. Therefore, such plants should be investigated to better understand their properties, safety and efficacy[12].

Euphorbia prostrata (*E. prostrata*) is an annual herb, which belongs to family Euphorbiaceae and is abundantly found in India and Africa. It has been traditionally used in several digestive system disorders[13,14]. In Burkina Faso, the leaves are used as a remedy against the bites of venomous insects (wasps, scorpions, etc.). In Togo, this plant is used to fight against infertility and menstrual pain[15] and in the western rural parts of Cameroon, the whole plant of *E. prostrata* is very often used for the treatment of dysentery and typhoid fever. The *in vitro* antimicrobial activity of *E. prostrata* extracts against *S. typhi*, *S. paratyphi* A, *S. paratyphi* B and *S. typhimurium* has been demonstrated in our previous work[16]. It was also shown that the aqueous extract of *E. prostrata* could be considered as practically non-toxic, since the LD₅₀ values of the extract were 23.2 g/kg and 26.4 g/kg for female and male mice, respectively[16]; i.e. the LD₅₀ values were greater than 5 g/kg, as stated by the Hodge and Sterner criteria[17].

In order to evaluate the therapeutic potentials of *E. prostrata* for the treatment of salmonellosis (e.g. typhoid fever, gastroenteritis), we investigated the *in vivo* anti-salmonella activity of the aqueous extract against *S. typhimurium*. The safety of this extract was also evaluated through subacute toxicological study.

2. Materials and methods

2.1. Plant material

The whole plants of *E. prostrata* Ait were collected from Dschang (West region of Cameroon) in April 2010, and identified by the Cameroon National Herbarium (Yaoundé), where a voucher specimen was deposited (Ref N 33585/HNC).

2.2. Test bacterium and culture medium

S. typhimurium was used in this study and was provided by the Centre Pasteur, Yaoundé, Cameroon. Bacterial strain was maintained on agar slant at 4 °C and sub-cultured on a fresh appropriate agar plate 24 h prior to antimicrobial test.

Salmonella-Shigella agar was used for the activation of *Salmonella*, and during *in vivo* assays in rats for bacterial counts and identification.

2.3. Experimental animals

Wistar Albino rats (aged 7-8 weeks, weighing 170-210 g) of either sex were used in the study. They were bred at the animal house of Department of Biochemistry, University of Dschang in the ambient environmental conditions [(23 ± 2) °C].

2.4. Chemicals for antimicrobial assay

Ciprofloxacin and cyclophosphamid were used as reference antibiotic and immunosuppressor, respectively.

2.5. Preparation of plant extract

The whole plant of *E. prostrata* was collected and air-dried at room temperature and then pulverised. The extraction (infusion) was done according to traditional healer indications. Thus 97.20 g of the powder were soaked for 15 min in 2 L of boiled distilled water. The preparation was filtered using Whatman No. 1 filter paper. The filtrate was then concentrated by allowing it to stand in an oven (Memmert) set at 45 °C.

2.6. In vivo assay using rats

Male and female Wistar Albino rats were used for this study. Each sex was divided into 7 groups of 5 animals each (i.e. M₀, M₁, M₂, M₃, M₄, M₅, and M₆ for males; F₀, F₁, F₂, F₃, F₄, F₅, and F₆ for females). The rats were acclimatized [room temperature (23 ± 2) °C, and a 12 h photoperiod] in cages (1 rat/cage) for one week before the commencement of the experiment. Salmonellosis was induced using the method proposed by Pan, et al[7], with modification. Briefly, rats were immunosuppressed by intraperitoneal injection with cyclophosphamid as described by Abhishek et al.[18] to facilitate the infection. At the third days of immunosuppression, the rats were fasted overnight and given, by gavage, 1 mL of saline solution (0.9% NaCl) containing 1.5 × 10⁸ CFU of *Salmonella typhimurium*, except animals of groups M₀ and F₀ (which were neither infected nor treated, and used as neutral control; they received distilled water). Animals of groups M₁ and F₁ (which were infected, but not treated) received distilled water during the treatment period, hence were used as negative control groups; and those of M₆ and F₆ received ciprofloxacin, and thus were used as positive control groups. To verify that infection has occurred, the bacterial load of the faeces of the animals was determined one day before infection and during four days following the infection: a steady increase in the bacterial load during the four days indicated the establishment of the infection. Graded doses (i.e. 26.34, 44.00, 73.48, 122.71 mg/kg) of the aqueous extract of *E. prostrata* were administered to rats in groups M₂ and F₂, M₃ and F₃,

M₄ and F₄, and M₅ and F₅, respectively, by gastric intubation for 14 consecutive days. These doses were chosen based on the traditional healer indications (*i.e.* 44 mg/kg body weight) and the minimum inhibitory concentration (MIC) result against *S. typhimurium* obtain in the previous work[16] (*i.e.* 26.34, 73.48, and 122.71 mg/kg body weight). The animals were maintained at room temperature [(23 ± 2) °C] with a 12 h light-dark cycle and standard animal feed and water were provided *ad libitum*. After administration of the bacterial suspension (inoculum), faecal samples were then collected every day and the numbers of the bacteria per gram of faeces were determined. In fact, faeces collected were dissolved in saline distilled water (0.9% NaCl) at the proportion of 1 g for 2 mL of suspension. Aliquots (100 µL) of faecal suspensions were serially diluted in saline distilled water (0.9% NaCl) and then plated on duplicate *Salmonella-Shigella* agar plates, which were subsequently incubated overnight at 37 °C. Typical colonies were then identified and counted on the plates. At the end of the treatment period, the biochemical, haematological and histological markers of possible side effects were evaluated in rats using standard methods and kits.

2.7. Collection of blood and preparation of serum sample

This was done according to the method used by Gatsing *et al*[19]. At the end of the treatment period, rats were anaesthetized using chloroform vapour prior to dissection. Blood samples were collected by cardiac puncture into two different tubes, one containing anticoagulant [ethylene diamine tetraacetic acid (EDTA)] and the other without anticoagulant. The blood in the tube with EDTA was used for the determination of haematological parameters, whereas that in the tube without EDTA was used for the preparation of serum samples. For serum preparation, the blood was allowed to clot by standing at room temperature for one hour and then refrigerated for another 1 h. The resultant liquid part was centrifuged at 1058 r/min for 10 min, and then the clear serum (supernatant) was isolated and stored at -30 °C until required for analysis.

2.8. Relative organ weight and preparation of homogenates

After taking the blood, the abdominal cavity of each animal was opened and organs, namely the heart, liver, lungs, spleen and kidneys, were quickly removed, cleaned with ice-cold saline, weighed and stored at 80 °C. The relative organ weight (organ to body weight ratio) of each animal was then calculated. The homogenates of various organs were prepared at 15% (15 g organ per 100 mL of 0.9% NaCl) as described by Gatsing *et al*[19]. This was done by grinding 500 mg of each organ in a mortar containing 3.34 mL saline distilled water (0.9% NaCl), placed on a block of ice. The homogenates were centrifuged at 1058 r/min for 15 min and the supernatants were then used for protein assays.

2.9. Haematological assays

White blood cell (WBC) count, red blood cell (RBC) count, hematocrit (Ht) and haemoglobin (Hb) concentration were all determined by use of an automated blood analyzer (QBC Autoread

Plus, UK). The blood samples were first pipetted into QBC capillary tubes and spun in a parafuge centrifuge (Becton Dickson, UK) for 5 min and read by means of an autoread analyzer.

2.10. Biochemical assays

The sera prepared above were used to estimate total cholesterol (TC), high-density lipoprotein (HDL) cholesterol, serum triglycerides (TG), low-density lipoprotein (LDL) cholesterol, aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Total cholesterol, HDL cholesterol and triacylglycerol were determined by enzymatic methods as described by Roeschlau, *et al*[20], using the kit Hospitex Diagnostics s.r.l. (Italy). The LDL cholesterol was calculated using the formula of Friedewald *et al*. [21]:

$$\text{LDL} = \text{TC} - \text{HDL} - (\text{TG}/5)$$

The atherosclerosis index (LDL/HDL) was calculated[22]. AST and ALT were assayed with the method described by IFCC[23], using the kit Hospitex Diagnostics s.r.l. (Italy). Serum creatinine and urinary creatinine were quantified by kinetic method of Newman and Prince[24], using the kit Hospitex Diagnostics s.r.l. (Italy). Total serum protein and organ proteins (liver, lungs, heart and spleen) were assayed by the Biuret method[25], while urinary proteins and kidney proteins were quantified by the method of Bradford[26].

2.11. Measurement of the percentage of weight gain, daily feed and water intakes

The amounts of feed and water consumed were measured daily from the quantity of feed and water supplied and the amount remaining after 24 h. The weight increase or weight loss of animals was evaluated daily and the percentage of weight gain was determined.

2.12. Histopathological analysis

Tissue cross sections were prepared and analyzed using conventional techniques described by Di Fiore[27]. After sacrificing the animals, small pieces of liver were fixed in 10% formalin, dehydrated in ascending grades of alcohol and cleared in xylene. The fixed tissue were embedded in paraffin wax and sectioned into five micrometres thick with the rotary microtome, then stained with hematoxylin and eosin. Then the sections were examined with light microscope and photographed using a microscopic camera.

2.13. Statistical analysis

Data obtained were expressed as mean ± SEM and were statistically analysed using One-way ANOVA. The Waller Duncan test was used to compare means of different groups. A *P*-value of < 0.05 was considered statistically significant.

2.14. Ethics

This work was carried out with respect for the welfare of animals, as recommended by WHO[28].

3. Results

3.1. In vivo antibacterial activity of aqueous extract of *E. prostrata* in rat

In general, the number of viable *S. typhimurium* recovered from faeces increased during the first day following the infection. The administration of *E. prostrata* extract was found to induce marked decreases on the number of viable *S. typhimurium* recovered from faeces as indicated by Figure 1. Animals (female and male) treated with different doses of the extract did not shed any viable *S. typhimurium* in faeces between the eighth and tenth days of the treatment period. The same observation was made for those treated with standard antibiotics between the fourth and sixth days of the treatment period. The number of viable *S. typhimurium* also decreased in the faeces of infected and untreated control animals, but this only occurred three to four days after that of the treated animals.

3.2. Effect of the extract on body weight trends, feed and water consumption

There were generally no significant changes ($P > 0.05$) in food and water consumption patterns (Table 1). However, an increase of percentage of weight gain in general for animals of both sexes was observed during the 14 days treatment period as shown by Figure 2.

Table 1

Food and water consumption of rats during *in vivo* studies.

Sex	Doses (mg/kg)	Food consumption (g)		Water consumption (mL)	
		1st week	2nd week	1st week	2nd week
Female	0	97.67 ± 28.32 ^a	109.14 ± 8.30 ^a	97.21 ± 7.07 ^a	90.60 ± 7.08 ^a
	0i	76.43 ± 35.52 ^b	92.86 ± 24.75 ^b	88.40 ± 3.36 ^a	74.00 ± 1.87 ^c
	26.34	91.43 ± 27.35 ^{ab}	101.14 ± 23.28 ^{ab}	94.00 ± 7.25 ^a	87.00 ± 3.70 ^{bc}
	44.00	91.86 ± 21.74 ^{ab}	104.29 ± 13.99 ^a	86.80 ± 7.26 ^a	76.40 ± 3.23 ^{bc}
	73.48	83.71 ± 19.43 ^b	109.57 ± 15.17 ^a	101.40 ± 3.37 ^a	95.60 ± 5.37 ^{ab}
	122.71	96.33 ± 33.41 ^a	109.14 ± 20.61 ^a	96.33 ± 7.26 ^a	94.64 ± 5.31 ^{ab}
Male	0	98.14 ± 24.77 ^a	116.57 ± 21.65 ^a	121.80 ± 4.96 ^a	106.57 ± 8.04 ^a
	0i	78.86 ± 35.21 ^b	94.71 ± 26.97 ^c	97.40 ± 4.79 ^a	94.20 ± 10.96 ^a
	26.34	92.86 ± 26.96 ^{ab}	102.14 ± 25.47 ^{bc}	107.80 ± 5.00 ^a	109.20 ± 6.18 ^a
	44.00	91.86 ± 21.74 ^{ab}	105.43 ± 15.59 ^b	104.00 ± 2.27 ^a	96.80 ± 5.46 ^a
	73.48	95.14 ± 26.90 ^{ab}	110.00 ± 15.74 ^{ab}	103.04 ± 2.25 ^a	106.00 ± 7.30 ^a
	122.71	94.29 ± 31.32 ^{ab}	110.57 ± 20.90 ^{ab}	113.80 ± 12.47 ^a	98.57 ± 11.52 ^a

Values are mean ± SEM of 5 determinations. Data in the same column in the same sex with different superscript letters are significantly different ($P < 0.05$). 0: non infected and untreated control group; 0i: infected and untreated group.




Figure 2. Body weight gain trend for female Wistar rats (A) and male Wistar rats (B) fed with aqueous extract of *E. prostrata* for 14 days. 0i: infected and untreated rats; 0 mg/kg: non infected and untreated rats (neutral and control). Each data point represents the mean ± SEM. ($n = 5$).

3.3. Effect of the extract on the relative organ weights after two weeks of treatment

The relative organ weights of liver, heart and spleen did not show any significant ($P > 0.05$) differences between the treated groups of both sexes and the neutral control groups (non infected and untreated groups). Meanwhile, in female rats there was a significant increase of the relative organ weight of kidneys at the dose of 122.71 mg/kg. A significant ($P < 0.05$) increase of the relative organ weight of lungs was observed at the doses of 26.34 mg/kg in female and 73.48 mg/kg in male (Table 2).





Figure 1. Effects of treatment with aqueous extract of *E. prostrata* on fecal shedding of *S. typhimurium* (CFU/g) by female (A) and male (B) rats.

Table 2

Effects of aqueous extract of *E. prostrata* on proteins profiles of liver, kidney, heart, spleen and lungs after 14 days of treatment.

Sex	Doses (mg/kg)	Proteins levels (mg/g of organs)				
		Liver	Spleen	Kidney	Heart	Lungs
Female	0	39.21 ± 0.49 ^{ab}	5.25 ± 1.07 ^{ab}	11.06 ± 0.57 ^c	3.93 ± 0.06 ^a	7.10 ± 0.52 ^b
	0i	36.84 ± 2.10 ^b	4.09 ± 0.42 ^b	11.49 ± 1.11 ^{bc}	3.65 ± 0.37 ^a	7.79 ± 2.62 ^b
	26.34	43.28 ± 3.99 ^a	6.51 ± 2.55 ^a	12.33 ± 0.63 ^b	4.21 ± 0.19 ^a	11.67 ± 1.75 ^a
	44.00	37.72 ± 2.99 ^{ab}	3.34 ± 1.59 ^b	10.82 ± 1.25 ^c	4.10 ± 0.26 ^a	8.55 ± 0.58 ^b
	73.48	43.21 ± 7.96 ^a	4.84 ± 0.31 ^{ab}	11.61 ± 0.27 ^{bc}	3.97 ± 0.36 ^a	8.55 ± 1.62 ^b
	122.71	43.47 ± 2.27 ^a	5.48 ± 1.36 ^{ab}	13.64 ± 0.82 ^a	4.81 ± 0.87 ^a	8.79 ± 0.56 ^b
Male	0	42.38 ± 6.45 ^a	5.23 ± 0.92 ^a	10.99 ± 1.15 ^{ab}	3.82 ± 0.56 ^a	7.17 ± 1.64 ^b
	0i	34.91 ± 6.05 ^b	5.06 ± 0.93 ^a	13.50 ± 3.28 ^a	4.13 ± 0.64 ^a	10.92 ± 1.77 ^a
	26.34	36.69 ± 3.78 ^{ab}	4.73 ± 0.94 ^a	10.43 ± 0.58 ^b	4.23 ± 0.13 ^a	6.80 ± 0.68 ^b
	44.00	38.45 ± 1.63 ^{ab}	4.12 ± 0.72 ^a	10.66 ± 1.39 ^{ab}	3.7 ± 0.14 ^a	8.19 ± 0.67 ^b
	73.48	40.84 ± 2.30 ^{ab}	5.02 ± 0.43 ^a	12.05 ± 1.10 ^{ab}	4.02 ± 0.18 ^a	9.98 ± 1.16 ^a
	122.71	39.75 ± 1.22 ^{ab}	4.74 ± 0.52 ^a	13.23 ± 2.47 ^{ab}	3.76 ± 0.11 ^a	7.17 ± 0.80 ^b

Values are mean ± SEM of 5 determinations. Data in the same column in the same sex with different superscript letters are significantly different ($P < 0.05$). 0: uninfected and untreated control group; 0i: infected and untreated group.

3.4. Effect of aqueous extract of *E. prostrata* on the haematological parameters of rats

The hematological analysis (Table 3) showed no significant ($P > 0.05$) changes in the RBC and WBC of rats (female and male), while there was a significant ($P < 0.05$) increase of Hb in females compared to the neutral control group. Also, there was a significant ($P < 0.05$) increase of Ht in males at the dose of 122.71 mg/kg, and no significant changes in female.

Table 3

Haematological parameters following 14-day treatment of rats with aqueous extract of *E. prostrata*.

Sex	Doses (mg/kg)	RBC	WBC	Hb	Ht
		($\times 10^6/\text{mm}^3$)	($\times 10^9/\text{mm}^3$)	(g/dL)	(%)
Female	0	6.2600 ± 0.9100 ^a	5.80 ± 0.84 ^b	12.00 ± 1.87 ^b	36.20 ± 1.92 ^a
	0i	2.6225 ± 1.1100 ^c	10.53 ± 1.30 ^a	16.05 ± 0.90 ^a	33.50 ± 2.36 ^a
	26.34	5.4600 ± 0.5400 ^{ab}	6.85 ± 0.60 ^b	15.15 ± 1.70 ^a	36.30 ± 7.95 ^a
	44.00	6.1000 ± 0.4100 ^{ab}	6.85 ± 2.41 ^b	15.05 ± 1.21 ^a	33.35 ± 2.36 ^a
	73.48	4.6800 ± 0.5060 ^b	5.08 ± 3.31 ^b	13.93 ± 1.88 ^{ab}	33.35 ± 1.85 ^a
	122.71	4.6300 ± 1.3800 ^a	6.10 ± 0.84 ^b	14.02 ± 1.86 ^a	35.50 ± 4.20 ^a
Male	0	6.2500 ± 0.9600 ^a	5.75 ± 1.26 ^{bc}	13.75 ± 1.50 ^a	35.00 ± 2.16 ^{bc}
	0i	4.8900 ± 0.9300 ^a	9.42 ± 2.71 ^a	15.28 ± 2.61 ^a	29.28 ± 4.25 ^c
	26.34	5.0000 ± 0.7070 ^a	5.70 ± 1.20 ^{bc}	15.00 ± 1.58 ^a	38.20 ± 5.59 ^{ab}
	44.00	5.9900 ± 0.6000 ^a	4.04 ± 0.95 ^c	13.40 ± 1.43 ^a	34.40 ± 5.27 ^{bc}
	73.48	5.8200 ± 1.3100 ^a	8.28 ± 4.03 ^{ab}	15.14 ± 1.59 ^a	39.08 ± 9.07 ^{ab}
	122.71	5.7500 ± 0.4400 ^a	5.00 ± 1.58 ^c	15.28 ± 2.61 ^a	42.86 ± 2.35 ^a

Values are mean ± SEM of 5 determinations. Data in the same column in the same sex with different superscript letters are significantly different ($P < 0.05$). 0: uninfected and untreated control group; 0i: infected and untreated group.

3.5. Effect of aqueous extract of *E. prostrata* on serum and urinary creatinine, serum and urinary proteins of rats

In general, no significant difference in serum and urinary creatinine level were observed in animals of both sexes (treated with different doses), compared to the neutral controls (non infected and untreated group). However, the extract caused a significant decrease of serum proteins at doses greater than or equal to 44 mg/kg in females, and a

significant increase of urinary proteins in the infected and untreated male group, compared to the neutral control group (Table 4). There were no significant differences in urinary proteins between the infected and untreated group and the treated male groups at all doses.

Table 4

Effects of aqueous extract of *E. prostrata* on serum creatinine, urinary creatinine, serum proteins and urinary proteins of rats after 14 days of treatment.

Sex	Dose (mg/kg)	Serum creatinine	Urinary creatinine	Serum proteins	Urinary proteins
		(mg/dL)	(mg/dL)	(mg/mL)	(mg/mL)
Female	0	0.35 ± 0.16 ^a	0.85 ± 0.14 ^b	104.40 ± 6.69 ^b	0.34 ± 0.07 ^{bc}
	0i	0.35 ± 0.22 ^a	1.45 ± 0.33 ^a	115.09 ± 14.64 ^{ab}	0.35 ± 0.55 ^{bc}
	26.34	0.40 ± 0.14 ^a	1.00 ± 0.25 ^b	123.18 ± 21.40 ^a	0.38 ± 0.16 ^{bc}
	44.00	0.35 ± 0.22 ^a	1.05 ± 0.33 ^{ab}	63.64 ± 9.30 ^{cd}	0.54 ± 0.06 ^a
	73.48	0.35 ± 0.14 ^a	0.90 ± 0.22 ^b	76.45 ± 17.86 ^c	0.30 ± 0.04 ^c
	122.71	0.40 ± 0.14 ^a	1.00 ± 0.35 ^b	53.63 ± 7.01 ^d	0.45 ± 0.06 ^{ab}
Male	0	0.30 ± 0.11 ^a	0.95 ± 0.21 ^b	80.92 ± 3.00 ^{abc}	0.37 ± 0.08 ^b
	0i	0.50 ± 0.25 ^a	1.60 ± 0.45 ^a	103.55 ± 12.01 ^a	0.51 ± 0.05 ^a
	26.34	0.35 ± 0.14 ^a	1.25 ± 0.31 ^{ab}	89.09 ± 38.71 ^{ab}	0.41 ± 0.02 ^{ab}
	44.00	0.45 ± 0.33 ^a	1.60 ± 0.80 ^a	46.46 ± 7.43 ^d	0.48 ± 0.05 ^{ab}
	73.48	0.30 ± 0.11 ^a	1.05 ± 0.11 ^{ab}	61.54 ± 34.79 ^{bcd}	0.52 ± 0.05 ^a
	122.71	0.30 ± 0.11 ^a	0.95 ± 0.21 ^b	53.55 ± 6.37 ^{cd}	0.52 ± 0.15 ^a

Values are mean ± SEM of 5 determinations. Data in the same column in the same sex with different superscript letters are significantly different ($P < 0.05$). 0: uninfected and untreated control group; 0i: infected and untreated group.

3.6. Effect of aqueous extract of *E. prostrata* on serum TC, HDL cholesterol, TG and index of atherosclerosis

The results of effect of aqueous extract of *E. prostrata* on the lipid profile after 14 days of treatment are summarized in Table 5. It appears from this table that the TG and the index of atherosclerosis showed non-significant changes in all treated animals (male and female, regardless of dose) compared to neutral control groups. The HDL cholesterol and TC showed significant ($P < 0.05$) decreases in treated females. In treated males, the TC and HDL cholesterol did not show any significant ($P > 0.05$) change compared to the neutral control. The LDL cholesterol showed significant ($P < 0.05$) decreases in females treated at doses of 26.34 and 73.48 and in male at dose of 26.34. The TC showed a significant ($P < 0.05$) decrease in infected and untreated male group.

Table 5

Effects of aqueous extract of *E. prostrata* on some lipid profiles after 14 days of treatment.

Sex	Dose (mg/kg)	TC	HDL cholesterol	LDL cholesterol	TG	Index of atherosclerosis
		(mg/dL)	(mg/dL)	(mg/dL)	(mg/dL)	
Female	0	124.40 ± 8.35 ^a	45.60 ± 5.90 ^a	62.200 ± 1.818 ^a	81.00 ± 3.16 ^a	1.750 ± 0.300 ^a
	0i	82.00 ± 5.43 ^c	32.60 ± 4.03 ^c	35.400 ± 0.722 ^c	70.00 ± 3.39 ^b	1.540 ± 0.340 ^a
	26.34	88.40 ± 12.05 ^c	33.00 ± 7.25 ^c	39.760 ± 4.284 ^{bc}	78.20 ± 2.58 ^a	1.730 ± 0.310 ^a
	44.00	108.80 ± 6.05 ^b	37.40 ± 5.45 ^{bc}	55.600 ± 0.154 ^a	79.00 ± 2.23 ^a	1.970 ± 0.580 ^a
	73.48	101.60 ± 8.96 ^b	40.40 ± 3.13 ^b	45.280 ± 5.602 ^b	79.60 ± 1.14 ^a	1.530 ± 0.350 ^a
	122.71	101.80 ± 8.90 ^b	38.20 ± 1.78 ^{bc}	47.200 ± 6.328 ^b	80.20 ± 3.96 ^a	1.680 ± 0.360 ^a
Male	0	101.40 ± 4.39 ^{ab}	35.80 ± 4.21 ^a	50.360 ± 0.532 ^a	76.20 ± 356 ^a	1.870 ± 0.390 ^a
	0i	72.60 ± 2.88 ^c	33.20 ± 2.28 ^c	26.080 ± 0.186 ^c	66.60 ± 2.07 ^b	1.190 ± 0.140 ^c
	26.34	93.40 ± 9.63 ^b	37.60 ± 4.04 ^a	40.320 ± 4.918 ^b	77.40 ± 3.36 ^a	1.490 ± 0.230 ^{bc}
	44.00	105.20 ± 6.98 ^a	36.60 ± 5.68 ^a	53.120 ± 0.406 ^a	77.40 ± 8.53 ^a	1.910 ± 0.313 ^a
	73.48	102.60 ± 9.29 ^{ab}	36.20 ± 2.86 ^a	50.200 ± 6.110 ^a	81.00 ± 1.58 ^a	1.840 ± 0.180 ^a
	122.71	98.60 ± 11.15 ^{ab}	36.20 ± 3.96 ^a	46.040 ± 6.370 ^{ab}	81.80 ± 4.09 ^a	1.730 ± 0.140 ^a

Values are mean ± SEM of 5 determinations. Data in the same column in the same sex with different superscript letters are significantly different ($P < 0.05$). 0: uninfected and untreated control group; 0i: infected and untreated group.




Figure 3. Histopathological changes in liver of infected rats after 14 days of treatment (400×). A: Intact lobular architecture and normal hepatocytes of infected and untreated rats; B: Dilation of sinusoid, inflammation of the parenchyma and the portal space, and cell degeneration were observed within the liver of infected and untreated rats; Hepatocytes with well-preserved nuclear to cytoplasmic ratio and very slight inflammation in groups F₃ (C), M₃ (D), F₄ (E), M₄ (F), M₅ (H); Focal inflammatory cells infiltration (*i.e.* more injury pattern) in groups F₅ (G) and F₆ (I); J: Slightly inflammatory cells infiltration and vascular congestion in group M₆.

3.7. Effect of aqueous extract of *E. prostrata* on serum transaminases

Table 6 summarizes the results of effect of aqueous extract of *E. prostrata* on serum transaminases (ALT and AST) after 14 days of treatment. AST activity was significantly elevated in infected and untreated control group and at doses greater than or equal to 44 mg/kg, as compared to uninfected and untreated control group, for females and males. Also, ALT activity was significantly increased at doses of 26.34, 44.00 and 73.48 mg/kg for females and at doses greater than or equal to 44.00 mg/kg for males.

Table 6

Transaminases (ALT and AST) levels in serum samples from animals treated with aqueous extract of *E. prostrata*.

Sex	Dose (mg/kg)	ALT (IU/L)	AST (IU/L)
Female	0	28.07 ± 2.98 ^b	60.51 ± 4.68 ^d
	0i	37.80 ± 3.42 ^a	83.60 ± 3.05 ^{bc}
	26.34	45.40 ± 5.77 ^a	76.80 ± 2.86 ^{cd}
	44.00	45.40 ± 10.16 ^a	96.40 ± 18.38 ^{ab}
	73.48	44.60 ± 6.54 ^a	102.40 ± 12.79 ^a
	122.71	37.75 ± 4.60 ^b	95.00 ± 23.10 ^{ab}
Male	0	35.68 ± 3.56 ^c	82.40 ± 5.03 ^b
	0i	40.20 ± 4.21 ^{bc}	91.00 ± 4.64 ^b
	26.34	38.00 ± 7.75 ^{bc}	88.80 ± 21.58 ^b
	44.00	46.27 ± 5.32 ^{ab}	114.40 ± 20.22 ^a
	73.48	55.00 ± 11.34 ^a	121.20 ± 21.29 ^a
	122.71	51.00 ± 8.71 ^a	124.00 ± 10.32 ^a

Values are mean ± SEM of 5 determinations. Data in the same column in the same sex with different superscript letters are significantly different ($P < 0.05$). 0: uninfected and untreated control group; 0i: infected and untreated group.

3.8. Effect of aqueous extract of *E. prostrata* on the histology of the liver sections

Histology of the liver sections (Figure 3) of uninfected and untreated control animals (neutral control), and of those infected and treated at doses ≤ 44 mg/kg showed normal hepatic cells with well-preserved cytoplasm, prominent nucleus and visible central

veins. The liver sections of infected and untreated control rats showed dilation of sinusoid, inflammation of the parenchyma and the portal space. At doses ≤ 44 mg/kg liver cross sections showed a normal appearance, similar to that of neutral control group. The histological architecture of liver sections of the animals treated with doses ≥ 73.48 mg/kg (females) and ≥ 122.71 mg/kg (males) of aqueous extract of *E. prostrata* showed injury pattern like significant inflammation of the parenchyma and the portal space, and vascular congestion.

4. Discussion

4.1. *In vivo* assay

Based on information provided by both the traditional healer and the *in vitro* antibacterial test results, *in vivo* study was undertaken in a view to verifying the therapeutic efficacy of the extract. Results of present research showed that the administration of aqueous extract of *E. prostrata* inhibited the growth of *S. typhimurium*, and thus reduced the numbers of viable *S. typhimurium* recovered from faeces. This reduction was dose dependent in animals infected and treated in both sexes, and their bacterial load was cancelled out within 8 to 10 days of treatment. All of these observations suggested that antimicrobial activity against *S. typhimurium* observed *in vitro* was maintained *in vivo*. The marked decrease of the bacterial load in infected animals after the start of the treatment could be due to the combined actions of the extract and the immune system, since a decrease was also observed in the negative controls (infected and untreated). However, this only occurred in the negative controls three to four days after that of the treated animals. This reduction of bacterial load in the negative controls could be explained by the regeneration of the immune system, since the latter was weakened to let the infection occur.

The use of *E. prostrata* in traditional medicine[29,30] could partly be justified by the above findings, and we believe that this plant extract could be a potential novel antimicrobial for the treatment of salmonellosis, including typhoid fever. Several metabolites from plant species, including alkaloids, tannins and sterols, have

previously been associated with antimicrobial activity[31,32]. The detection of these classes of secondary metabolites in the extract[16] could explain the observed activities.

The protein must be eliminated in very small quantities in urine. Therefore, an increase in their removal is a sign of glomerular damage[33]. The extract appears to significantly increase the concentration of urinary protein in females treated at dose of 44.00 mg/kg, and in males at doses greater or equal to 73.48 mg/kg. This increased rate of urinary protein may indicate a renal toxicity that the extract could induce in these animals. Meanwhile, the significant increase observed in female between non infected and untreated, and infected and untreated may be attributed to the infection.

4.2. Hematological study

The hematological status after 14 days of oral administration of aqueous extract of *E. prostrata* was also assessed. In general the results showed that the values for the RBC, WBC, Hb and Ht were not significantly different as compared to the neutral control groups and fell within the normal range. The anaemia observed in infected and untreated female control as indicated by the RBC count could possibly be attributed to the various pathophysiological effects produced during *Salmonella* infection in rodent. Proliferation of *Salmonella* in rodents, controlled by a gene Nramp[34], could lead to chronic cell lysis due to the presence of free radicals produced during inflammatory reactions[35]. It has been established that the degree of anaemia always correlates well with increase in parasitemia[36].

4.3. Lipid profile

Numerous studies have pointed out the increased risk of coronary disorders with elevated levels of TC, TG, and LDL-cholesterol[37]. In a study on apparently healthy women, it has been observed that levels of TC, LDL-cholesterol, and the ratio of TC to HDL-cholesterol were significantly associated with increased risk of ischemic stroke[38]. High level of serum TC and LDL-cholesterol have been shown to pose a significant risk in ischemic stroke, whereas high levels of HDL-cholesterol indicated beneficial effects on the atherosclerotic process[39]. A high LDL/HDL ratio has also been reported to have a high predictive value of a first coronary event[22]. In the present study, it was observed that administration of aqueous extract of *E. prostrata* to rats did not induce significant changes in the serum levels of TC, TG, and HDL-cholesterol in male, while the levels of TC and HDL-cholesterol decrease significantly in female. Beside, no significant increase of LDL cholesterol and atherosclerosis index were observed in animals of both sex. This result suggests that *E. prostrata* contains component which may have no risk of cardiovascular and coronary diseases.

4.4. Transaminase and microscopic examination

Transaminases are enzymes that catalyze the transfer of an amino group from an amino acid to an α -keto acid. The increase in transaminase levels in the blood is indeed indicative of a number

of ailments[40]. The AST and ALT are enzymes commonly used as markers of hepatic necrosis[41-43]. ALT is localized primarily in hepatocytes, whereas AST is found in most tissues including the heart, kidneys and liver[44]. In case of hepatotoxicity, ALT and AST increase simultaneously in serum, but the ALT increase persists longer than the AST[45]. In this study, AST was significantly elevated in infected and untreated control group and at doses greater than or equal to 44.00 mg/kg, as compared to uninfected and untreated control group, for females and males. Also, ALT activity was significantly increased at doses of 26.34, 44.00 and 73.48 mg/kg for females and at doses greater than or equal to 44 mg/kg for males, suggesting hepatic damage. The elevation of these parameters in infected and untreated control is due to the infection. In fact during typhoid fever, there is an increase of serum transaminase activity[46,47], which reflects liver damage, due to the accumulation of bacteria at this level[48].

The attribution of the increase in serum ALT and AST enzymes to liver damage was further strengthened by microscopic examination of liver sections. Histology of the liver sections of uninfected and untreated control animals (neutral control), and of those infected and treated at doses of 44 mg/kg showed normal hepatic cells with well-preserved cytoplasm, prominent nucleus and visible central veins. The liver sections of infected and untreated control rats showed dilation of sinusoid, inflammation of the parenchyma and the portal space that may be attributed to infection. The same observation was made by Choi *et al.*[49] on the liver of mice infected with *S. typhimurium* and untreated. At doses of 44.00 mg/kg liver cross sections showed a normal appearance, similar to that of neutral control group. Therefore, the extract at these doses would not only treat the infection, but might have corrected liver cell damage caused by the infection. The histological architecture of liver sections of the animals treated with doses of 73.48 mg/kg (females) and 122.71 mg/kg (male) of aqueous extract of *E. prostrata* showed injury pattern like significant inflammation of the parenchyma and the portal space, and vascular congestion. This may be explained by the fact that at relatively high doses, the extract had the ability to induce liver damage. However, the apoptosis or necrosis of hepatocytes remains one of the major signs of liver damage due to toxic compounds[50], and this was not observed in this study.

The overall results of the present work provide baseline information for the possible use of the aqueous extract of *E. prostrata* in the treatment of salmonellosis, especially typhoid fever. In addition to antibacterial activity, the data reported from acute toxicity showed that the extract may be non toxic. These observations can justify the traditional use of the plant in the treatment of typhoid fever. Moreover, the *in vivo* antibacterial activity revealed that the dose of extract obtained from (or used by the) traditional healer may be considered as relatively safe, as shown by the results of subacute toxicity evaluation. However, the extract may induce slight liver damage at high doses. Subchronic and chronic toxicity studies are necessary to further support the safe use of this plant. It is also necessary to extrapolate these results in large animals.

Conflict of interest statement

The authors declare that there is no conflict of interest.

Acknowledgements

We would like to express our gratitude to the Pasteur Centre, Yaoundé, Cameroon, for providing the test bacterium.

Comments

Background

Typhoid fever is an important global health problem in Africa where sanitary conditions are inadequate and access to clean water is limited. Since the use of conventional antibiotics is costly, there has been considerable interest in the use of plants as an alternative method to control the disease. This study showed that extract of *E. prostrata* Aiton could stop salmonellosis after 8-10 days of treatment of infected rats, with non toxic doses. However, the hematological, biochemical and histopathological analyses indicated that at higher doses, the extract could induce liver and kidney damage. This study showed that *E. prostrata* can be used for the treatment of typhoid fever with satisfactory efficacy and safety.

Research frontiers

The present study shows that extract of *E. prostrata* Aiton could stop typhoid fever at normal doses after 8 to 10 days and evaluated the hematological, biochemical and histopathological side effect of the use of relatively higher doses.

Related reports

Various parts (*i.e.*, flowers, leaves, barks and roots) of *Cassia petersiana* were selected and tested against *S. typhi*, *S. paratyphi* A and *S. paratyphi* B. This was with a view to ascertaining and assessing their traditionally claimed antityphoid properties.

Innovations and breakthroughs

It has been reported that *E. prostrata* Aiton can be used for the treatment of grade I and II of hemorrhoids with satisfactory efficacy and safety (Gupta, 2011). In this work authors have demonstrated that the aqueous extract of this plant can be used in the treatment of typhoid fever.

Applications

This study gave the scientific basis of the use of *E. prostrata* Aiton.

Peer review

In the present study, it was observed that the aqueous extract of *E. prostrata* Aiton can be used in the treatment of typhoid fever with satisfactory efficacy and safety. However, hematological, biochemical and histopathological analyses indicated that, at relatively higher doses, the liver and kidney could be damaged. Information generated in this study could be the reference for the routine use of aqueous extract of the aforementioned plant in the treatment of typhoid fever after extrapolation in human being.

References

- [1] Christenson JC. *Salmonella* infections. *Pediatr Rev* 2013; **34**(9): 375-83.
- [2] Mandell GL, Bennett JE, Dolin R. *Mandell, Douglas, and Bennett's principles and practice of infectious diseases*. 7th ed. Philadelphia: Churchill Livingstone Elsevier; 2011.
- [3] Typhoid fever surveillance and vaccine use, South-East Asia and Western Pacific Regions, 2009-2013. *Wkly Epidemiol Rec* 2014; **89**(40): 429-39.
- [4] Gatsing D, Adoga GI. Antisalmonellal activity and phytochemical screening of the various parts of *Cassia petersiana* Bolle (Caesalpinaceae). *Res J Microbiol* 2007; **2**(11): 876-80.
- [5] Medalla F, Sjölund-Karlsson M, Shin S, Harvey E, Joyce K, Theobald L, et al. Ciprofloxacin-resistant *Salmonella enterica* serotype typhi, United States, 1999-2008. *Emerg Infect Dis* 2011; **17**(6): 1095-8.
- [6] Suez J, Porwollik S, Dagan A, Marzel A, Schorr YI, Desai PT, et al. Virulence gene profiling and pathogenicity characterization of non-typhoidal *Salmonella* accounted for invasive disease in humans. *PLoS One* 2013; **8**(3): e58449.
- [7] Pan XL, Yang Y, Zhang JR. Molecular basis of host specificity in human pathogenic bacteria. *Emerg Microbes Infect* 2014; **3**: e23.
- [8] Song J, Willinger T, Rongvaux A, Eynon EE, Stevens S, Manz MG, et al. A mouse model for the human pathogen *Salmonella typhi*. *Cell Host Microbe* 2010; **8**(4): 369-76.
- [9] Inácio MC, Carmona F, Paz TA, Furlan M, da Silva FA, Bertoni BW, et al. Screening test for antibiotics in medicinal plants (STAMP): using powdered plant materials instead of extracts. *Am J Plant Sci* 2013; **4**(12): 2340-50.
- [10] Samy RP, Manikandan J, Al Qahtani M. Evaluation of aromatic plants and compounds used to fight multidrug resistant infections. *Evid Based Complement Alternat Med* 2013; doi: 10.1155/2013/525613.
- [11] World Health Organization. WHO guideline for the assessment of herbal medicines. WHO Expert Committee on specifications for pharmaceutical preparations-WHO technical report series no. 863, thirty-fourth report. Geneva: World Health Organisation; 1996. [Online] Available from: <http://apps.who.int/medicinedocs/en/d/Js5516e/> [Accessed on 20th May, 2014]
- [12] Al Akeel R, Al-Sheikh Y, Mateen A, Syed R, Janardhan K, Gupta VC. Evaluation of antibacterial activity of crude protein extracts from seeds of six different medical plants against standard bacterial strains. *Saudi J Biol Sci* 2014; **21**(2): 147-51.
- [13] Baptista MM, Ramos MA, de Albuquerque UP, Coelho-de-Souza G, Ritter MR. Traditional botanical knowledge of artisanal fishers in southern Brazil. *J Ethnobiol Ethnomed* 2013; **9**: 54.
- [14] Gupta PJ. The efficacy of *Euphorbia prostrata* in early grades of symptomatic hemorrhoids - a pilot study. *Eur Rev Med Pharmacol Sci* 2011; **15**: 199-203.
- [15] Schmelzer GH, Gurib-Fakim A. *Plant resources of Tropical Africa (Program). Plant resources of tropical Africa: medicinal plants 1*. Vol 11. Wageningen: PROTA Foundation; 2008.
- [16] Kengni F, Tala DS, Djimeli MN, Chegaing Fodouop SP, Kodjio N, Magnifouet HN, et al. *In vitro* antimicrobial activity of *Harungana madagascariensis* and *Euphorbia prostrata* extracts against some pathogenic *Salmonella* sp. *Int J Biol Chem Sci* 2013; **7**(3): 1103-18.

- [17] Ouédraogo S, Somé N, Ouattara S, Kini FB, Traore A, Bucher B, et al. Acute toxicity and vascular properties of seed of *Parkia biglobosa* (JACQ) R. Br Gift (Mimosaceae) on rat aorta. *Afr J Tradit Complement Altern Med* 2011; **9**(2): 260-5.
- [18] Shah AS, Wakade AS, Juvekar AR. Immunomodulatory activity of methanolic extract of *Murraya koenigii* spreng leaves. *Indian J Exp Biol* 2008; **46**: 505-9.
- [19] Gatsing D, Aliyu R, Kuate JR, Garba IH, Tedongmo N, Tchouanguép FM, et al. Toxicological evaluation of the aqueous extract of *Allium sativum* bulbs on laboratory mice and rats. *Cameroon J Exp Biol* 2005; **1**: 39-45.
- [20] Roeschlau P, Bernt E, Gruber W. Enzymatic determination of total cholesterol in serum. *Z Klin Chem Klin Biochem* 1974; **12**: 226.
- [21] Friedewald WT, Levy RI, Frederickson DS. Estimation of concentration of the low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. *Clin Chem* 1972; **18**: 499-502.
- [22] Mertz DP. [Atherosclerosis-index (LDL/HDL): risk indicator in lipid metabolism disorders]. *Med Klin* 1980; **75**(4): 159-61. German.
- [23] Siekmann L, Bonora R, Burtis CA, Ceriotti F, Clerc-Renaud P, Féraud G, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 7. Certification of four reference materials for the determination of enzymatic activity of gamma-glutamyltransferase, lactate dehydrogenase, alanine aminotransferase and creatine kinase accord. *Clin Chem Lab Med* 2002; **40**(7): 739-45.
- [24] Newman DJ, Price CP. Renal function and nitrogen metabolites. In: Burtis CA, Ashwood. ER, editors. *Tietz textbook of clinical chemistry*. 3rd ed. Philadelphia : W.B. Saunders Company; 1999, p. 1204-70.
- [25] Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the biuret reaction. *J Biol Chem* 1949; **177**: 751-66.
- [26] Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976; **72**: 248-254.
- [27] Di Fiore MSH. *An atlas of human histology*. 2nd ed. Philadelphia: Lea and Febiger; 1963.
- [28] World Health Organization. Research guidelines for evaluating the safety and efficacy of herbal medicines. Geneva: World Health Organization; 1993. [Online] Available from: <http://apps.who.int/medicinedocs/en/d/Jh2946e/> [Accessed on 20th May, 2014]
- [29] Saeed-ul-Hassan S, Bhatti MU, Khalil-ur-Rehman M, Niaz U, Waheed S, Rasool S, et al. Irritant effects of *Euphorbia prostrata*. *Afr J Pharm Pharmacol* 2013; **7**(33): 2321-32.
- [30] Kamgang R, Gonsu Kamga H, Wafo P, Mbungi NJA, Pouokam EV, Fokam TMA, et al. Activity of aqueous ethanol extract of *Euphorbia prostrata* Ait. on *Shigella dysenteriae* type 1-induced diarrhea in rats. *Indian J Pharmacol* 2007; **39**(5): 240-4.
- [31] Chavasco JM, Prado E Felipe BH, Cerdeira CD, Leandro FD, Coelho LF, Silva JJ, et al. Evaluation of antimicrobial and cytotoxic activities of plant extracts from southern Minas Gerais cerrado. *Rev Inst Med Trop Sao Paulo* 2014; **56**(1): 13-20.
- [32] Ogutu AI, Lilechi DB, Mutai C, Bii C. Phytochemical analysis and antimicrobial activity of *Phytolacca dodecandra*, *Cucumis aculeatus* and *Erythrina excelsa*. *Int J Biol Chem Sci* 2012; **6**(2): 692-704.
- [33] Schaffer A, Menche N. [Anatomy, physiology, biology]. 2nd ed (translated from German 4th ed). France: Medicine – Science; 2004. French.
- [34] Brown DE, Libby SJ, Moreland SM, McCoy MW, Brabb T, Stepanek A, et al. *Salmonella enterica* causes more severe inflammatory disease in C57/BL6 Nrap1G169 mice than Sv129S6 mice. *Vet Pathol* 2013; **50**(5): 867-76.
- [35] Droy-Lefaix MT, Bueno L. [Diarrhea and inflammatory cascade: a new approach]. *Acta Endoscopica* 2003; **33**: 773-80. French.
- [36] Bhawna S, Bharti A, Yogesh K, Reena A. Parasitemia and hematological alterations in malaria: a study from the highly affected zones. *Iranian J Pathol* 2013; **8**(1): 1-8.
- [37] Kapur NK, Ashen D, Blumenthal RS. High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. *Vasc Health Risk Manag* 2008; **4**(1): 39-57.
- [38] Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, Gaziano JM. Lipid levels and the risk of ischemic stroke in women. *Neurology* 2007; **68**: 556-62.
- [39] Uddin MJ, Alam B, Jabbar MA, Mohammad QD, Ahmed S. Association of lipid profile with ischemic stroke. *Mymensingh Med J* 2009; **18**(2): 131-5.
- [40] Kumar S, Amarapurkar A, Amarapurkar D. Serum aminotransferase levels in healthy population from western India. *Indian J Med Res* 2013; **138**: 894-9.
- [41] Olaleye MT, Amobonye AE, Komolafe K, Akinmoladun AC. Protective effects of *Parinari curatellifolia* flavonoids against acetaminophen-induced hepatic necrosis in rats. *Saudi J Biol Sci* 2014; **21**(5): 486-92.
- [42] Suganthi V, Gowri S, Gurusamy K. Hepatoprotective activity of *Cayratia carnosa* on liver damage caused by lead acetate in rats. *J Nat Prod Plant Resour* 2013; **3**(2): 76-9.
- [43] Bidie ADP, Koffi E, Yapi FH, Yémié AA, Djaman JA, Guede-Guina F. Evaluation of the toxicity of a methanolic total extract of *Mitragyna ciliate* a natural anti-malaric. *Int J Biol Chem Sci* 2010; **4**(5): 1509-18.
- [44] Singh A, Bhat TK, Sharma OP. Clinical biochemistry of hepatotoxicity. *J Clin Toxicol* 2011; doi:10.4172/2161-0495.S4-001.
- [45] Hyder MA, Hasan M, Mohieldin AH. Comparative levels of ALT, AST, ALP and GGT in liver associated diseases. *Eur J Exp Biol* 2013; **3**(2): 280-4.
- [46] Klotz SA, Jorgensen JH, Buckwold FJ, Craven PC. Typhoid fever. An epidemic with remarkably few clinical signs and symptoms. *Arch Intern Med* 1984; **144**(3): 533-7.
- [47] Adeyi AO, Jinadu AM, Arojoye OA, Alao OO, Ighodaro OM, Adeyi OE. *In vivo* and *in vitro* antibacterial activities of *Momordica charantia* on *Salmonella typhi* and its effect on liver function in typhoid-infected rats. *J Pharmacogn Phytother* 2013; **5**(11): 183-8.
- [48] Khan KH, Jain SK. Regular intake of *Terminalia chebula* can reduce the risk of getting typhoid fever. *Adv Biotechnol* 2009; **8**(9): 10-5.
- [49] Choi JG, Kang OH, Lee YS, Chae HS, Oh YC, Brice OO, et al. *In vitro* and *in vivo* antibacterial activity of *Punica granatum* peel ethanol extract against *Salmonella*. *Evid Based Complement Alternat Med* 2011; doi: 10.1093/ecam/nep105.
- [50] Eroschenko VP. *Di Fiore's atlas of histology with functional correlations*. 9th ed. Philadelphia: Lippincott. Williams and Wilkins; 2000.